Akeso's bispecific antibody ivonescimab has shown a 34% reduction in death risk for advanced squamous non-small cell lung cancer patients in the phase three HARMONi-6 trial. Patients on ivonescimab plus chemotherapy survived a median 27.9 months versus 23.7 months on the current standard therapy (tislelizumab plus chemotherapy), with 64.7% alive at two years compared to 48.6% in the control group. The results earned a spot at ASCO's plenary session — the first Chinese-originated oncology drug to do so in 61 years. Summit Therapeutics holds exclusive US/EU/Canada/Japan rights and has filed a BLA with the FDA, with a target action date of November 2026. The trial positions ivonescimab to compete in a $20B+ NSCLC market and signals China's biotech industry maturing from generics to globally competitive innovative drugs.
